Table 4.
PS/PSN compounds that bind AGFs and inhibit pro-angiogenic biological activities in vitro and/or angiogenesis in vivo.
| polysulfated compounds | target AGF |
|---|---|
| unmodified and chemically modified heparin/HS | VEGF [146,147,148,149], FGF2 [2,150,151,152], HGF, PDGF [153,154,155], Tat [1,156,157], midkine [158], angiogenin [159], angiopoietin [160], pleiotrophin [161] |
| chondroitin sulfate | FGF2 [150], PDGF [162], midkine [158], peliotrophin [161] |
| oligosaccharides from alginic acid of seaweed | VEGF [163] |
| polysaccharides from Antrodia cinnamomea | VEGF [154] |
| carrageenans | FGF2 [164,165] |
| fucoidan | VEGF, FGF2 [166,167] |
| SargA (from Sargassum Stenofillum) | FGF2 [168] |
| dermatan sulfate | FGF2 [150], HGF [169] |
| laminarin sulfate | FGF2 [170] |
| SPMG | FGF2 [171], Tat [172] |
| sulfatides | FGF2 [144], HGF [173], midkine [174] |
| dextran sulfate | VEGF, FGF2 [175,176], HGF [177] |
| exopolysaccharide from Alteromonas infernos | VEGF, FGF2 [178] |
| heparin-carrying polystyrene | VEGF, FGF2, HGF [179] |
| heparin oligomer glycodendrimers | FGF2 [180] |
| heparin-mimicking sulfated peptides | VEGF [181] |
| suleparoide (HS analog) | FGF2 [182] |
| K5 derivatives | FGF2 [183,184], Tat [185] |
| PI-88 and analogs | VEGF, FGF2 [186,187] |
| RGTAs (synthetic GAG) | VEGF [188], FGF2 [189] |
| sucrose octasulfate | FGF2 [190] |
| beta-(1->4)-galacto oligosaccharides | FGF2 [191] |
| PPS | FGF2 [192], Tat [193] |
| β-cyclodextrin | FGF2 [194], Tat [195] |
| PSN compounds | target AGF |
| suramin | VEGF [196], FGF2 [197,198] |
| suramin analogs | VEGF, PDGF [199], FGF2 [200], Tat [29,201] |
| PSS | FGF2 [202], Tat [203] |